Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895.

Abstract

Publication types

  • Expression of Concern